Valantine Hannah 4

What Happened
Valantine Hannah, a director of CareDx, was granted 9,795 restricted stock units (RSUs) on 2026-06-12 (reported as an award at $0 cost) and sold 12,103 CareDx shares in an open-market transaction on 2026-06-15 for a weighted average price of $23.11, totaling approximately $279,728. The RSU grant vests 100% on the earlier of the one-year anniversary of the grant or the day before the first annual meeting after the grant, subject to continued service.

Key Details

• Grant: 9,795 RSUs on 2026-06-12 (reported as acquisition A at $0) — vesting: 100% at earlier of 1-year anniversary or day before first annual meeting after grant (service condition).
• Sale: 12,103 shares on 2026-06-15 (sale, S) — weighted average price $23.11; total proceeds ≈ $279,728. Sales executed at prices ranging $23.00–$23.30.
• Sale executed pursuant to a Rule 10b5-1 trading plan adopted Dec 11, 2025.
• Shares owned after the transactions are not specified in the provided filing.
• Filing date: 2026-06-16. No indication the Form 4 was filed late.

Context
RSU grants are awards that vest later (not immediate cash), so the 9,795 RSUs do not represent immediately tradable shares until vesting conditions are met. The June 15 sale was made under a pre-established 10b5-1 plan, which typically schedules trades in advance and is common for insiders. The sale value (~$280k) is a factual disclosure and should not be taken alone as a signal of the director’s views about the company.